> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Joint Panel to Review NDA for Pain Drug
- URL: https://www.fdaweb.com/joint-panel-to-review-nda-for-pain-drug/
- Published: 2017-07-10T12:00:00.000Z
- Updated: 2026-09-14T22:32:49.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139092

*Federal Register* notice: FDA has announced a 7/26 joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee. The panel will review and discuss an Intellipharmaceutics Corp. NDA for oxycodone hydrochloride extended- release oral tablets with a proposed indication of management of moderate-to-severe pain when a continuous around-the-clock analgesic is needed for an extended period of time. The product has been formulated with properties intended to deter abuse. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-07-03/pdf/2017-13887.pdf?ref=fdaweb.com).